{"cluster": 36, "subcluster": 14, "abstract_summ": "LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening.Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary.Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS.We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ).", "title_summ": "BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release SyndromeUse of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case ReportTocilizumab administration in a refractory case of COVID-19Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome", "title_abstract_phrases": "Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release SyndromeYounger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening.Tocilizumab may have a role in treating severe COVID-19 patients with CRS.Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case ReportNovel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China.LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS."}